Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 3Colorectal Neoplasms 2Breast Neoplasms 2Solid Tumors 1Ovarian Neoplasms 1Multiple Myeloma 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1

Interventions

Paclitaxel 12Gemcitabine 9atezolizumab 8Carboplatin 8Bevacizumab 6tocilizumab 4navitoclax 4liposomal doxorubicin 4Irinotecan 4Erlotinib Hydrochloride 4Cetuximab 4Sunitinib 3Oxaliplatin 3Leucovorin 3Injections 3Fluorouracil 3Docetaxel 3Cyclophosphamide 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2tislelizumab 2temsirolimus 2ridaforolimus 2plocabulin 2pembrolizumab 2pazopanib 2olaparib 2obinutuzumab 2linifanib 2fludarabine 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumors × dalotuzumab × Clear all
NCT01431547 2016-06-17

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Merck Sharp & Dohme LLC

Phase 1 Completed
21 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡